{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:16:11Z","timestamp":1791357371146,"version":"4.3.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.psychres.2016.10.053","type":"journal-article","created":{"date-parts":[[2016,11,3]],"date-time":"2016-11-03T08:31:12Z","timestamp":1478161872000},"page":"750-755","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Long-acting injectable antipsychotics for the prevention of relapse in patients with recent-onset psychotic disorders: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"246","author":[{"given":"Taro","family":"Kishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Oya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakao","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1\u20133","key":"10.1016\/j.psychres.2016.10.053_bib1","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.schres.2013.02.016","article-title":"Antipsychotic treatment dosing profile in patients with schizophrenia evaluated with electronic monitoring (MEMS(R))","volume":"146","author":"Acosta","year":"2013","journal-title":"Schizophr. Res."},{"issue":"1\u20133","key":"10.1016\/j.psychres.2016.10.053_bib2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.schres.2012.05.007","article-title":"Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies","volume":"139","author":"Alvarez-Jimenez","year":"2012","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.psychres.2016.10.053_bib3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.schres.2011.06.029","article-title":"Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory","volume":"132","author":"Bartzokis","year":"2011","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.psychres.2016.10.053_bib4","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.psychres.2014.10.016","article-title":"Stigma, discrimination and medication adherence in schizophrenia: results from the Swedish COAST study","volume":"220","author":"Brain","year":"2014","journal-title":"Psychiatry Res."},{"issue":"5","key":"10.1016\/j.psychres.2016.10.053_bib5","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/2045125314540297","article-title":"The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal","volume":"4","author":"Brissos","year":"2014","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.psychres.2016.10.053_bib6","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrn3475","article-title":"Power failure: why small sample size undermines the reliability of neuroscience","volume":"14","author":"Button","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"issue":"3","key":"10.1016\/j.psychres.2016.10.053_bib7","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.psc.2007.04.002","article-title":"Antipsychotic medication adherence in schizophrenia","volume":"30","author":"Byerly","year":"2007","journal-title":"Psychiatr. Clin. N. Am."},{"issue":"10","key":"10.1016\/j.psychres.2016.10.053_bib8","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1586\/ern.09.96","article-title":"Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study","volume":"9","author":"De la Gandara","year":"2009","journal-title":"Expert Rev. Neurother."},{"issue":"1\u20133","key":"10.1016\/j.psychres.2016.10.053_bib9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.schres.2013.05.016","article-title":"The evidence for illness progression after relapse in schizophrenia","volume":"148","author":"Emsley","year":"2013","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.psychres.2016.10.053_bib10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/YCO.0000000000000160","article-title":"Ambiguous findings concerning potential advantages of depot antipsychotics: in search of clinical relevance","volume":"28","author":"Haddad","year":"2015","journal-title":"Curr. Opin. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2016.10.053_bib11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/15622975.2012.739708","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects","volume":"14","author":"Hasan","year":"2013","journal-title":"World J. Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.psychres.2016.10.053_bib12","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/15622975.2012.696143","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance","volume":"13","author":"Hasan","year":"2012","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2016.10.053_bib13","unstructured":"Higgins, J., Green, S.J., 2011. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 The Cochrane Collaboration \u3008www.cochrane-handbook.org\u3009."},{"issue":"7414","key":"10.1016\/j.psychres.2016.10.053_bib14","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.psychres.2016.10.053_bib15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1192\/S0007125000291514","article-title":"The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation","volume":"7","author":"Kay","year":"1989","journal-title":"Br. J. Psychiatry Suppl."},{"issue":"2","key":"10.1016\/j.psychres.2016.10.053_bib16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/2045125312464106","article-title":"Patients' and clinicians' attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis","volume":"3","author":"Kirschner","year":"2013","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.psychres.2016.10.053_bib17","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/schbul\/sbs150","article-title":"Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials","volume":"40","author":"Kishimoto","year":"2014","journal-title":"Schizophr. Bull."},{"issue":"9657","key":"10.1016\/j.psychres.2016.10.053_bib18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.psychres.2016.10.053_bib19","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia","volume":"166","author":"Leucht","year":"2009","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2016.10.053_bib20","first-page":"5","article-title":"Maintenance treatment with antipsychotic drugs for schizophrenia","author":"Leucht","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"10.1016\/j.psychres.2016.10.053_bib21","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3371\/CSRP.MACH.061213","article-title":"An exploratory, open-label, randomized trial comparing risperidone long-acting injectable with oral antipsychotic medication in the treatment of early psychosis","volume":"9","author":"Malla","year":"2016","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"issue":"10","key":"10.1016\/j.psychres.2016.10.053_bib22","doi-asserted-by":"crossref","first-page":"885","DOI":"10.4088\/JCP.v63n1006","article-title":"Risperidone, 2 mg\/day vs. 4 mg\/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning","volume":"63","author":"Merlo","year":"2002","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2016.10.053_bib23","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.psc.2007.04.007","article-title":"Epidemiology of schizophrenia: review of findings and myths","volume":"30","author":"Messias","year":"2007","journal-title":"Psychiatr. Clin. N. Am."},{"key":"10.1016\/j.psychres.2016.10.053_bib24","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.psychres.2016.10.053_bib25","unstructured":"NICE, 2014. Psychosis and Schizophrenia in Adults: Treatment and Management: Updated Edition 2014, London."},{"issue":"2","key":"10.1016\/j.psychres.2016.10.053_bib26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1017\/S1461145704004262","article-title":"A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis","volume":"7","author":"Oosthuizen","year":"2004","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"10","key":"10.1016\/j.psychres.2016.10.053_bib27","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1177\/0269881109104882","article-title":"Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years","volume":"24","author":"Patel","year":"2010","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.psychres.2016.10.053_bib28","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archpsyc.56.3.241","article-title":"Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder","volume":"56","author":"Robinson","year":"1999","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.psychres.2016.10.053_bib29","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0920-9964(01)00312-7","article-title":"Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder","volume":"57","author":"Robinson","year":"2002","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.psychres.2016.10.053_bib30","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/schbul\/sbi032","article-title":"Pharmacological treatments for first-episode schizophrenia","volume":"31","author":"Robinson","year":"2005","journal-title":"Schizophr. Bull."},{"issue":"1\u20133","key":"10.1016\/j.psychres.2016.10.053_bib31","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.schres.2015.08.015","article-title":"Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia","volume":"169","author":"Schreiner","year":"2015","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.psychres.2016.10.053_bib32","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1600-0447.1994.tb01501.x","article-title":"A typological model of schizophrenia based on age at onset, sex and familial morbidity","volume":"89","author":"Sham","year":"1994","journal-title":"Acta Psychiatr. Scand."},{"issue":"3","key":"10.1016\/j.psychres.2016.10.053_bib33","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2174\/15748847113089990051","article-title":"The pharmacokinetics of long-acting antipsychotic medications","volume":"9","author":"Spanarello","year":"2014","journal-title":"Curr. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.psychres.2016.10.053_bib34","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1001\/jamapsychiatry.2015.0270","article-title":"Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trial","volume":"72","author":"Subotnik","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"10.1016\/j.psychres.2016.10.053_bib35","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.4088\/JCP.09m05284yel","article-title":"A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome","volume":"70","author":"Weiden","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"9904","key":"10.1016\/j.psychres.2016.10.053_bib36","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(13)61611-6","article-title":"Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010","volume":"382","author":"Whiteford","year":"2013","journal-title":"Lancet"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178116309477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178116309477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T05:55:28Z","timestamp":1572674128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178116309477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":36,"alternative-id":["S0165178116309477"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2016.10.053","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-acting injectable antipsychotics for the prevention of relapse in patients with recent-onset psychotic disorders: A systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2016.10.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}